Global Financial Private Client’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

Global Financial Private Client’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-47	Closed	-$2.36K	–	661
2022 Q2	$2.36K	Sell	47 -4,217	-99%	-$214K	﹤0.01%	508
2022 Q1	$265K	Buy	+4,264	New	+$269K	0.13%	132

Other funds holding GNOM

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

MIG

McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return

OCM

One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Global Financial Private Client's GNOM Position: Q3 2022 in Review

Global Financial Private Client sold out of Global X Genomics & Biotechnology ETF (GNOM) in Q3 2022, closing a stake of 47 shares — an estimated $2.36K sold.

Global Financial Private Client first reported a position in GNOM in Q1 2022 and held it in 2 quarters. The position peaked at $265K in Q1 2022. 58 funds tracked by Wall St. Rank hold GNOM as of Q3 2022.

Global Financial Private Client reported no remaining Global X Genomics & Biotechnology ETF position as of Q3 2022 after selling out during the quarter.
Global Financial Private Client sold 47 Global X Genomics & Biotechnology ETF shares in Q3 2022, an estimated $2.36K.
Global Financial Private Client first reported a position in Global X Genomics & Biotechnology ETF in Q1 2022 and held it in 2 quarters.
Global Financial Private Client's Global X Genomics & Biotechnology ETF position peaked at $265K in Q1 2022.
58 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q3 2022.

Based on Global Financial Private Client's 13F filing for Q3 2022, filed 16 May 2024.